Get the Stockscreener App
2.74
4.98%
0.13
After Hours:
2.89
0.15
+5.47%
Inflarx Nv stock is traded at $2.74, with a volume of 1.64M.
It is up +4.98% in the last 24 hours and up +85.14% over the past month.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$2.61
Open:
$2.72
24h Volume:
1.64M
Relative Volume:
1.10
Market Cap:
$403.58M
Revenue:
$208.60K
Net Income/Loss:
$-58.59M
P/E Ratio:
-2.99
EPS:
-0.9164
Net Cash Flow:
$-47.11M
1W Performance:
+15.61%
1M Performance:
+85.14%
6M Performance:
+130.25%
1Y Performance:
+48.11%
1-Day Range:
$2.68
$2.94
1-Week Range:
$2.27
$2.94
52-Week Range:
$0.7113
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
2.74 | 384.43M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx Nv Stock (IFRX) Latest News
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline - MSN
Long term debt to total assets ratio of InflaRx N.V. – HAM:IF0 - TradingView
Discontinued operations of InflaRx N.V. – HAM:IF0 - TradingView
EBIT per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. Cash Flow – HAM:IF0 - TradingView
InflaRx N.V. Balance Sheet – HAM:IF0 - TradingView
InflaRx N.V. Statistics – HAM:IF0 - TradingView
Non-controlling/minority interest of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx NV stock (NL0012661870): what’s behind the latest trading volatility after Gohibic’s slo - AD HOC NEWS
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Nigeria
IFRX Technical Analysis | Trend, Signals & Chart Patterns | INFLARX NV (NASDAQ:IFRX) - ChartMill
InflaRx NV stock (NL0012661870): May data from a recent YTD ranking - AD HOC NEWS
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Farallon funds and managers report shared stakes in InflaRx (IFRX) - Stock Titan
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
Raymond James upgrades InflaRx NV (IFRX) - MSN
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential - Investing.com UK
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential By Investing.com - Investing.com South Africa
InflaRx NV Stock (IFRX): Favorable Izicopan Data Released - AD HOC NEWS
TradingKey - TradingKey
TCG Crossover III and Chen Yu disclose 9.8% stake in InflaRx (IFRX) - Stock Titan
InflaRx NV stock (NL0012661870): HC Wainwright raises price target to $8 - AD HOC NEWS
Number of shareholders of InflaRx N.V. – NASDAQ:IFRX - TradingView
Number of shareholders of InflaRx N.V. – TRADEGATE:IF0 - TradingView
InflaRx N.V. Completes $150 Million Underwritten Offering of Ordinary Shares to Advance Pipeline Activities - Moomoo
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026 - The Globe and Mail
IFRX - Finviz
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal DiseasesSlideshow (NASDAQ:IFRX) 2026-05-08 - Seeking Alpha
Transcript : InflaRx N.V.Special Call - marketscreener.com
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - Barchart.com
InflaRx Unveils Izicopan Strategic Shift And $150m Offering - Citeline News & Insights
InflaRx completes $150 million stock offering at $2 per share By Investing.com - Investing.com Australia
InflaRx completes $150 million stock offering at $2 per share - Investing.com
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - The Manila Times
75 million new InflaRx shares raise cash to fund drug pipeline - Stock Titan
Press Release: InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - Moomoo
InflaRx (NASDAQ: IFRX) raises $150M in underwritten share sale - Stock Titan
EDGAR Filing Documents for 0001140361-26-019440 - SEC.gov
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq - Insider Monkey
InflaRx (NASDAQ: IFRX) raises $150M via 75M-share offering to fund izicopan - Stock Titan
Form 424B5 InflaRx N.V. - StreetInsider
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx attracts strong investor interest with US share offering turning to kidney - European Biotechnology Magazine
Inflarx Nv Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):